Biotechnology Industry
Filter News
Found 10,299 articles
-
The Biotechnology Industry Organization (BIO) published the fifth edition of the Building the Bioeconomy report recently. The report studied 28 different indicators and provided analysis and insight into the biotech environment for 33 countries. The goal of the report is to determine how successf...
-
Interview: Survey Numbers Show California’s Life Science Industry Is an Economic Powerhouse
11/20/2018
The number of life science jobs grew by 12,500 for an approximate total of a total estimated employment of 311,226. That was music to the ears of Sara Radcliffe, president and chief executive officer of the California Life Sciences Association. -
Seqirus, a wholly owned subsidiary of CSL, is expanding its manufacturing plant in North Carolina. It expects to invest $140 million in the expansion.
-
PellePharm’s Phase III Skin Disease Trial Is Back on Track Following Agreement With LEO Pharma
11/20/2018
Denmark-based LEO Pharma and California rare disease drugmaker PellePharm entered into a strategic collaboration worth $760 million to address unmet needs in multiple orphan skin diseases, such as Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), two rare forms of skin cancer. -
Five Prime Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference
11/20/2018
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference, November 28, 2018
-
Revance to Participate in Upcoming Investor Conferences
11/20/2018
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.
-
Curis to Present at the 60th Annual Meeting of the American Society of Hematology
11/20/2018
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations at the 60th annual meeting of the American Society of Hematology.
-
Ascletis and Roche enter exclusive Pegasys partnership in China for viral Hepatitis
11/20/2018
Shanghai Roche Pharmaceuticals Ltd. and Ascletis BioScience Co., Ltd. jointly announce that starting from 1st Dec 2018, Ascletis and Roche will expand their partnership in viral Hepatitis.
-
BioInvent Signs Manufacturing Agreement With U.S. Cell Therapy Company
11/20/2018
BioInvent International AB announced today that it has signed a manufacturing agreement with an undisclosed U.S. cell therapy company for the production of cGMP compliant material to support their clinical development programs.
-
Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)
11/20/2018
Ipsen and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177Lu-IPN01087 (formerly known as 3BP-227).
-
Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018
11/20/2018
Three panels with 13 KOLs highlighting migraine, glutamate and inflammation platforms
-
Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint
11/20/2018
The study achieved its primary efficacy endpoint (p<0.0001)
-
Tiziana Announces Pricing of Offering and Warrant Conversion Raising in Aggregate $5.79 million of New Equity Capital, Approval to List on the Nasdaq Global Market and Loan Conversion Extinguishing $1.78 million of Debt
11/20/2018
Tiziana Life Sciences plc today announces the pricing of its underwritten initial public offering in the United States (the “Offering”) of 442,910 American Depositary Shares ("ADSs"), representing 4,429,100 new ordinary shares of nominal value £0.03 each in the capital of the Company ("Ordinary Shares") at an initial public offering price of $9.90 per ADS, before underwriting discounts and commissions.
-
BioSpace Movers and Shakers for Nov. 19
11/19/2018
Companies bolstered their leadership with additions to boards of directors and c-suite offices. -
Tesaro, located in Waltham, Mass., is rumored to be up for sale. The rumors caused shares to rocket as much as 39 percent on Friday, but it’s not the first time rumors have floated that the company might be on the auction block.
-
It is estimated that 2.5 percent of all children in the U.S. might have a peanut allergy. Since 2010, according to the America College of Allergy, Asthma and Immunology, incidence of peanut allergies in children had risen 21 percent in the U.S.
-
Roivant Sciences and iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic SAL200
11/19/2018
- Roivant plans to initiate Phase 2 clinical trial in 2019
-
vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
11/19/2018
vTv Therapeutics Inc. today announced that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City.
-
Sobi™ Appoints Paula Treutiger as Head of Communications and Investor Relations
11/19/2018
Swedish Orphan Biovitrum AB has appointed Paula Treutiger as Head of Communications and Investor Relations. Paula will join Sobi on 1 January 2019 and be part of Sobi's Executive Committee.
-
Generation Bio to Present at the 2018 Evercore ISI Healthcare Conference
11/19/2018
Generation Bio today announced that the company will present at the Evercore ISI Healthcare Conference in Boston, MA.